Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

VEGF Receptor-2 Antagonist

Ramucirumab, LY3009806, IMC‑1121B

Phase 3

Gastric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Hepatocellular Carcinoma
Ramucirumab, LY3009806, IMC‑1121B
NSCLC
Ramucirumab, LY3009806, IMC‑1121B

Phase 2

Gastric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B
Pediatric Cancer
Ramucirumab, LY3009806, IMC‑1121B

Phase 1

Advanced Solid Tumors
Ramucirumab, LY3009806, IMC‑1121B
Experimental Dosing
Ramucirumab, LY3009806, IMC‑1121B
NSCLC
Ramucirumab, LY3009806, IMC‑1121B

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.